PTIX · XBRL financial data

Protagenic Therapeutics, Inc.\new financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (PTIX's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY26Jun 30, 2026
Revenue	0	0	0*	0	0	0	0*	0	—	0*	0*	—
Research and development	836	1,124	1,011*	1,461	1,196	324	135	880	273	154	81*	110
General and administrative	307	308	201*	278	453	288	50	568	160	155	(158)*	98
Total operating expenses	1,144	1,432	1,212*	1,738	1,667	652	401	1,448	1,114	925	120*	961
Operating income (loss)	(1,144)	(1,432)	(1,212)*	(1,738)	(1,667)	(652)	(401)	(1,448)	(1,114)	(925)	(120)*	(961)
Interest income	85	69	54*	14	9	11	9*	8	—	—	—	—
Interest expense	32	32	13*	—	—	—	—	—	—	—	—	—
Income tax expense (benefit)	—	—	—	—	—	(3)	—	—	—	—	—	—
Net income (loss)	(1,210)	(1,397)	(1,676)*	(1,724)	(1,607)	(641)	(850)	(1,440)	(869)	2,211	5,084*	(964)
Earnings per share, basic USD per share	(0.28)	(0.32)	(0.38)*	(0.39)	(0.36)	(0.14)	(0.16)	(2.75)	(0.47)	1.14	—	(0.53)
Earnings per share, diluted USD per share	(0.28)	(0.32)	(0.38)*	(0.39)	(0.36)	(0.14)	(0.16)	(2.75)	(0.47)	1.14	—	(0.53)
Weighted average shares, basic thousands of shares	4,331	4,331	4,398*	4,435	4,443	4,529	5,396	523	1,849	1,935	—	1,810
Weighted average shares, diluted thousands of shares	4,331	4,331	4,398*	4,435	4,443	4,529	5,396	523	1,849	1,935	—	1,810

† Share count changed about 1/13 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PTIX's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY26Jun 30, 2026
Cash and cash equivalents	219	153	1,288	2	925	71	80	15	2,722	2,213	1,509	566
Marketable securities	5,823	5,119	2,768	1,592	—	—	—	—	—	—	—	—
Inventory	—	—	—	—	—	—	—	1	1	1	—	—
Total current assets	6,918	5,377	4,200	2,468	1,369	1,423	1,883	928	2,858	2,299	1,543	710
Property and equipment, net	2	56	123	111	98	86	73	60	51	39	15	6
Total assets	6,919	5,433	4,323	2,579	1,467	1,508	1,956	989	5,003	4,431	3,650	2,796
Accounts payable	—	—	—	—	—	—	—	961	1,641	2,030	950	1,000
Accrued liabilities	—	—	—	—	—	—	—	249	408	253	82	73
Total current liabilities	1,505	1,280	655	446	675	789	943	1,077	9,703	6,824	1,031	1,073
Total liabilities	1,505	1,280	655	446	675	789	943	1,077	9,703	6,824	1,031	1,073
Accumulated deficit	(27,705)	(29,102)	(30,778)	(32,502)	(34,109)	(34,749)	(36,303)	(37,743)	(11,325)	(9,114)	(4,030)	(4,993)
Total stockholders' equity	5,414	4,153	3,668	2,132	793	719	1,013	(88)	(4,701)	(2,393)	2,619	1,723
Total liabilities and equity	6,919	5,433	4,323	2,579	1,467	1,508	1,956	989	5,003	4,431	3,650	2,796
Common shares outstanding (cover page) thousands of shares	4,331	4,435	4,435	4,435	4,467	6,795	7,526	589	1,935	1,810	1,810	1,810

† Share count changed about 1/13 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (PTIX's year ends in late March)

In thousands of dollars	Q2 FY23Jun 30, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25†Mar 31, 2025	Q2 FY26Sep 30, 2025	Q3 FY26Dec 31, 2025	Q4 FY26Mar 31, 2026	Q1 FY26Jun 30, 2026
Net income (loss)	(1,210)	(1,397)	(1,676)*	(1,724)	(1,607)	(641)	(850)	(1,440)	(869)	2,211	5,084*	(964)
Stock-based compensation	167*	167*	167*	162	265*	250*	245*	236	106*	96*	92*	67
Net cash from operating activities	(1,532)*	(656)*	(1,144)*	(1,659)	(1,552)*	(186)*	(354)*	(1,068)	(812)*	(510)*	266*	(944)
Net cash from investing activities	1,612*	591*	2,278*	1,203	1,600*	0*	(1,220)*	—	0*	0*	(313)*	—
Proceeds from issuing common stock	—	—	—	—	—	—	0*	0*	0*	0*	0*	—
Net cash from financing activities	—	—	—	—	—	317*	1,371*	103	(599)*	(0)*	(534)*	—
Net change in cash	81*	(66)*	1,135*	(456)	93*	131*	783*	(966)	—	—	—	—

† Share count changed about 1/13 in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.
A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Protagenic Therapeutics, Inc.\new	566	not reported	(944)	1.8M	0.6 quarters	Q1 FY26 10-QJun 30, 2026
Biomerica	2,733	1,265	(802)	4.6M	3.4 quarters	Q1 FY27 10-QAug 31, 2026
Adial Pharmaceuticals	28,712	not reported	(6,363)*	2.6M	4.5 quarters	Q2 FY26 10-Q/AJun 30, 2026
AIM ImmunoTech	9,900	26	(4,590)*	30.4M	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Vyome Holdings	7,888	27	(904)*	7.0M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
CV Sciences	266	2,985	20*	225.8M	—	Q2 FY26 10-QJun 30, 2026
Minerva Neurosciences	24,652	not reported	(13,345)*	47.7M	5.6 quarters	Q2 FY26 10-QJun 30, 2026
PharmaCyte Biotech	17,739	0	(781)	10.7M	22.8 quarters	Q1 FY27 10-QJul 31, 2026
Neuphoria Therapeutics	19,866	year only	1,214*	5.4M	—	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.